Anti-Ro/SSA antibodies may help predict interstitial lung disease (ILD) risk in systemic sclerosis (SSc) patients. A study found these antibodies increased the odds of ILD by 1.24 but did not predict progression or survival. Researchers suggest incorporating these antibodies into clinical practice for ILD screening, particularly in patients without SSc-specific antibodies. Despite limitations in the study, the findings show potential in risk-stratifying SSc patients with anti-Ro/SSA antibodies and monitoring lung involvement. This approach could be expanded to other rheumatic diseases to predict lung complications and improve patient care.
Source link
Anti-Ro/SSA Antibodies Have Potential to Predict ILD in SSc
